fbpx Skip to main content

The Journal of the American Society of Nephrology reported that sickle cell trait is associated with higher doses of erythropoiesis-stimulating agents during dialysis to manage anemia. Sickle cell trait is present in 6 to 8% of African Americans and is usually not considered problematic. However, some individuals with sickle cell trait have been diagnosed with renal abnormalities. 

African Americans on dialysis frequently need higher doses of erythropoiesis-stimulating agents than patients of other ethnicities, leading researchers at the University of North Carolina at Chapel Hill to investigate a possible connection. Dr. Vimal Derebail and his colleagues included six months’ worth of medical records from 5,319 African American patients on hemodialysis. As expected, the Black patients required 13% more medication to achieve the same hemoglobin levels as non-Black patients.

Sickle cell trait was present in 10% of Black study participants. The researchers concluded that sickle cell trait may explain the increased need for erythropoiesis-stimulating agents seen in African American patients on dialysis compared with Caucasian patients on dialysis. Dr. Derebail said that decisions on treating anemia in dialysis should take this research into account. Further study into sickle cell trait and kidney failure should also be undertaken [1].

Source:

[1] Derebail, V. K., Lacson, E. K., Kshirsagar, A. V., Key, N. S., Hogan, S. L., Hakim, R. M., Mooney, A., Jani, C. M., Johnson, C., Hu, Y., Falk, R. J., & Lazarus, J. M. (2014). Sickle Trait in African-American Hemodialysis Patients and Higher Erythropoiesis-Stimulating Agent Dose. Journal of the American Society of Nephrology, 25(4), 819–826. https://doi.org/10.1681/asn.2013060575

Share this article
You May Also Like::  A Racial Matter: Sickle Cell Patients Denied Healthcare Funding